JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $8 price target.
JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $8 price target.